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Abstract Vitamin D research has gained increased attention
in recent times due to its roles beyond bone health and calcium
homeostasis, such as immunomodulation. In some parts of the
brain and on immune cells, vitamin D hydroxylating enzymes
and its receptors are located. Epidemiological evidence dem-
onstrates that deficiency of Vitamin D is relevant for disease
risk and course in multiple sclerosis (MS) and presumably
also in neuromyelitis optica spectrum disorders (NMOSD),
Parkinson’s disease (PD), and Alzheimer’s disease (AD).
Although the exact mechanism underlying vitamin D effects
in these diseases remains widely unexplored, human and an-
imal studies continue to provide some hints. While the major-
ity of vitamin D researchers so far speculate that vitamin D
may be involved in disease pathogenesis, others could not
show any association although none have reported that suffi-
cient vitamin D worsens disease progression. The studies pre-
sented in this review suggest that whether vitamin Dmay have
beneficial effects in disease course or not, may be dependent
on factors such as ethnicity, gender, diet, vitamin D receptor
(VDR) polymorphisms and sunlight exposure. We here re-
view the possible role of vitamin D in the pathogenesis and
disease course of MS, NMOSD, PD, and AD and potential
therapeutic effects of vitamin D supplementation which may
be relevant for predictive, preventive, and personalized med-
icine. We suggest areas to consider in vitamin D research for
future studies and recommend the need to supplement patients
with low vitamin D levels below 30 ng/ml to at least reach
sufficient levels.
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Introduction
Vitamin D has gained increased attention in diverse areas of
biomedical research due to its role that goes beyond skeletal
and calcium (Ca) metabolism [1, 2]. The impact of vitamin D
has been studied in cardiovascular diseases [3], neuroinflam-
mation [4, 5], and neurodegenerative diseases [6] among
others. This is not surprising as the receptors of vitamin D
and the enzyme (α1-hydroxylase) needed for its activation
are located in many internal organs, immune cells, and also
key areas of the brain [7].
Epidemiological evidence suggests that in many countries
across the globe, vitamin D deficiency is prevalent across all
age groups, irrespective of the geographical location [8] or
seasonal changes [9] as well as in healthy subjects [10].
The endogenous metabolism of vitamin D is mediated by
ultraviolet (UV) B radiation converting 7-dehydrocholesterol
in the skin to cholecalciferol. Hydroxylation of cholecalciferol
in the liver then leads to 25-hydroxyvitamin (25(OH)D with a
subsequent hydroxylation step producing the active form
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1,25-dihydroxyvi tamin D3 also known as 1,25-
dihydroxycholecalciferol (1,25(OH)2D) in the kidneys [11].
In this review, the use of the term vitaminD refers to 25(OH)D
or 1,25(OH)2D3 unless otherwise stated.
Inadequate vitamin D levels are pertinent to the pathogen-
esis of multiple sclerosis (MS) and presumably also of neuro-
myelitis optica spectrum disorders (NMOSD), Parkinson’s
disease (PD), and Alzheimer’s disease (AD). In all these dis-
eases, it is reported that patients tend to have low serum vita-
min D levels compared to healthy controls [12–14].
Prospective studies and meta-analyses have demonstrated
that low serum or plasma vitamin D levels increased the risk
of dementia [15, 16], cognitive impairment [12, 13], impaired
motor functions [17, 18], and memory decline [19] which are
all characteristics of neurodegenerative diseases. Additionally,
evidence from cross-sectional studies has shown the impact of
vitamin D deficiency on falls and balance in Parkinson’s dis-
ease (PD) [17].
In the context of autoimmune diseases, administration of
vitamin D prevented the onset of experimental autoimmune
encephalomyelitis (EAE), a rodent model of MS [20]. In an
animal model of AD, dietary supplements with vitamin D
enhanced learning and memory compared to healthy controls
[21].
We here review the possible role of vitamin D in the path-
ogenesis and disease course of MS, NMOSD, PD, and AD
and potential therapeutic effects of vitamin D supplementation
which may be relevant for predictive and/or personalized
medicine and may inform individualized treatment strategies
for patients with these often debilitating neuroinflammatory
and neurodegenerative diseases.
Vitamin D beyond bone mineralization and Ca
metabolism
Besides the fundamental effects of vitamin D on skeletal
health and Ca homeostasis, several other important functions
have been identified. In this section, we summarize the
neurosteroid properties of vitamin D beyond Ca homeostasis
in relation to neuroinflammatory, neurodegenerative, and au-
toimmune diseases.
The modulation of the innate and adaptive immune system
is an important function of vitamin D [22–24]. Literally, all
cells of the immune system express the vitamin D receptor as a
prerequisite for being amenable to vitamin D signaling.
Furthermore, many immune cells show 1α-hydroxylase activ-
ity, suggesting auto- and paracrine immune regulation via lo-
cal 1,25(OH)2D3 vitamin D concentrations at the sites of in-
flammation. For further details, we refer the reader to a recent
comprehensive review of the detailed effects of vitamin D on
immune cell subsets [24]. Specifically, in MS an established
important immunomodulatory effect of vitamin D is the in-
duction of tolerogenic dendritic cells from human monocytes,
which promote the differentiation of regulatory rather than
pro-inflammatory T cells [25]. Additionally, it supports the
differentiation of naïve CD4+ Tcells into immunomodulatory
T helper 2 (Th2) and regulatory T cells rather than pro-
inflammatory Th1 and Th17 cells. It also interferes with anti-
body production by plasma cells [26] and inhibits the produc-
tion of pro-inflammatory cytokines such as interferon gamma
and tumor necrosis factor (TNF) alpha by cytotoxic CD8+ T
cells.
Additionally, several lines of evidence point to the neuro-
protective role of vitamin D. Increased activity of L-type volt-
age-sensitive calcium channels (LVCC) has long been shown
to induce aging as well as increased cell death in the hippo-
campus of rats [27, 28]. Reports from animal studies and
neuronal cell cultures have shown that 25(OH)D or the active
metabolite 1,25(OH)2D3 prevents neurotoxicity by downreg-
ulating LVCC [29]. Specifically, in AD, vitamin D is shown to
mediate the clearance of amyloid beta plaques (Aβ) through
the activation of macrophages [30]. The clearance of Aβ
protected against apoptosis which usually induces oxidative
stress resulting in damage in the brain of AD patients [30, 31].
On the other hand, vitamin D is known to enhance neuronal
survival by regulating neurotrophic factor-3 (NT-3) and Glial-
derived neurotrophic factor (GDNF) synthesis in an animal
model of AD [32, 33].
Not only is vitamin D presumably neuroprotective; it also
plays important roles in synaptic plasticity. In an animal model
of AD, administration of vitamin D restored the otherwise low
extracellular postsynaptic potentials in the cornu ammonis 3, 1
(CA3, CA1) regions of the hippocampus [34] since vitamin D
receptors are located here.
Sunlight exposure and disease risk
Several studies have found that sunlight exposure attenu-
ates disease course in many diseases such as MS and PD
among others due to its influence on circulating vitamin D
levels. UV radiation accounts for 90% of serum vitamin D
while the contribution of dietary sources is less relevant
[35, 36]. In PD, exposure to sunlight was shown to en-
hance bone mineral density by boosting vitamin D levels
in the serum [37]. A population-based study also showed
an increase in disability worsening in MS patients with
reduced sunlight exposure [38].
The positive correlation between MS prevalence in differ-
ent areas of the world and latitude is long known [39].
Interestingly, a link between sun exposure and MS incidence
can be observed already on a less global level. In France for
example, MS prevalence shows a strong inverse association
with the mean annual UVB radiation as southern areas with
higher annual UVB radiation levels show lower MS preva-
lence than northern areas with lower UVB radiation levels
[40]. In regions of higher latitude (50.0–56.0°), the onset of
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MS was found to be 2 years earlier than those in lower lati-
tudes (19.0–39.9°) [41]. Exception from the latitude gradient
rule can be at least partially explained by genetic differences
and/or lifestyle including dietary variations [42]. For example,
a lower MS prevalence than one would expect from the lati-
tude was observed in regions such as Norway with a high
consumption of fatty vitamin D-rich fish [43]. A recent study
supplemented relapsing-remitting MS patients with deficient
levels of serum vitamin D (≤ 24 nmol/l or ≤ 9.6 ng/ml). It was
found that each nanomoles per liter increase in serum vitamin
D levels lead to a − 0.014 (95% CI − 0.026 to − 0.003) reduc-
tion in the annualized relapse rate [44].
Several studies including a recent meta-analysis demon-
strated that spring borns have a significantly higher lifetime
MS risk than those born in autumn, which has been attributed
at least in part to an insufficient in utero vitamin D supply
because of low maternal vitamin D serum levels during winter
[45–48]. Likewise, the level of sun exposure during childhood
and adolescence, e.g., by outdoor leisure activities which may
serve as a proxy for vitamin D supply in early life, has been
inversely linked to the risk of MS in adulthood [49–52].
Although tempting, these studies are limited by the inevitably
biased retrospective determination of past sun exposure and
the possibility of intrinsic vitamin D independent effects of
sun or UVB exposure itself on the disease [53–55].
In the next sections, we review the role of vitamin D inMS,
NMOSD, PD, and AD.
The role of vitamin D in multiple sclerosis and EAE
MS is considered the most common chronic inflammatory
disorder of the CNS in western countries and — as it is an
incurable disease — a leading course of disability and
early retirement in young adults, predominantly females
of child-bearing age [56–59]. Worldwide, about 2.5 mil-
lion people suffer from MS [60]. Clinically, MS is char-
acterized by recurrent subacute bouts of CNS dysfunction
including but not limited to central motor system dysfunc-
tion, optic neuritis, coordination, balance and sensory dis-
turbances, cognitive dysfunction [61], and fatigue
[62–64]. Pathophysiologically, autoreactive encephalito-
genic T cells in concert with B cells and cells of the innate
immune system orchestrate an autoimmune reaction
against CNS structures which results in demyelination
and neuroaxonal damage of the brain, retina, and spinal
cord from earliest disease stages on [65–72]. Both genetic
and environmental factors contribute to the individual risk
of MS. Several lines of evidence which are discussed in
more detail below suggest vitamin D as an environmental
factor to impact both the risk to develop MS as well as the
course of the already established disease. In experimental
autoimmune encephalomyelitis (EAE), the animal model
of MS, vitamin D was shown to modulate both innate and
adaptive immune responses and has prophylactic and ther-
apeutic effects.
In the next section, we discuss the (1) geographical and
seasonal associations of vitamin D with the risk and course
of MS, (2) associations between vitamin D supply or serum
levels in early years and the risk to develop MS later, (3)
relations between serum levels and clinical and/or
radiographical disease activity, and finally, (4) data from in-
terventional clinical trials.
Prophylactic and therapeutic effects of vitamin D in EAE
In the active EAE model which is still the best established
rodent animal model for MS [73], immunization of healthy
mice with myelin proteins results in MS-like CNS inflamma-
tion and ascending flaccid paresis after several days. Dietary
treatment of mice with vitamin D starting from disease induc-
tion (prophylactic paradigm) resulted in a reduced incidence
and severity of the disease. Likewise, starting vitamin D treat-
ment at the onset of symptoms (therapeutic paradigm) ame-
liorated the course and severity of the disease. Withdrawal of
vitamin D leads to a resumption of disease activity [20, 74].
These early studies suggested that higher serum vitamin D
levels are both preventive and therapeutic in autoimmune en-
cephalomyelitis. Interestingly, in a later study, benefits of vi-
tamin D were only observed in female but not in male mice
which suggest gender differences in the protective role of
vitamin D at least in the animal model [75]. Clearly, these
results cannot be directly transferred to the human situation.
Relations between vitamin D levels and disease activity
Does vitamin D level impact the risk of MS, and if so, what is
the most vulnerable period during a lifetime? These important
questions are methodologically difficult to answer.
Prospective population-based studies do not exist, and epide-
miological or observational studies are usually limited by ret-
rospective design, selection bias, and interferencewith various
confounders. A nested case-control study using stored serum
samples from US Army members suggested a decreasing risk
of MS with increasing past vitamin D serum levels. In fact, a
50 nmol/l (20 ng/ml) increase in serum 25(OH)D decreased
the odds to develop MS to 0.59 (95% confidence interval, CI
0.36–0.97) in the white population. In black and Hispanic
populations, there was no significant association between vi-
tamin D levels and MS risk with odds of 0.66 (95% CI 0.24–
1.78; p = 0.41) and 0.97 (95% CI 0.28–3.33; p = 0.96), re-
spectively [76]. Likewise, in a large-scale long-term cohort
study, the risk of MS was inversely associated with the dietary
vitamin D intake. The relative risk in the highest quintile of
total vitamin D intake compared with those in the lowest was
0.67 (95% CI 0.40 to 1.12) [77]. Extending the above
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discussed data on childhood and adolescence as critical pe-
riods, recent data suggest that already in the uterus supply of
vitamin D and, as recently shown in a Danish population-
based case-control study, neonatal vitamin D may impact the
risk of MS later in life [78, 79].
In established disease, several lines of evidence consistent-
ly suggest that higher serum levels are associated with a more
favorable disease course, i.e., fewer relapses and less MRI
activity. MS patients have lower serum levels than matching
healthy controls, and lower levels can be detected during re-
lapses compared to phases of remission [80]. Importantly,
levels are already lower at disease onset, which argues against
insufficient levels being a consequence of disease (reverse
causality), for example by reduced sunshine exposure due to
disability with subsequently reduced mobility (less outdoor
activities) [81]. Several studies consistently showed an inverse
relationship between vitamin D levels and frequency of re-
lapses, disability progression, and occurrence of new brain
MRI lesions [82–88]. In one study, for example, doubling of
serum levels were associated with a reduction of relapse rate
by 27% [82], and in another study in pediatric MS, every
10 ng/ml increase in vitamin D levels was associated with a
34% reduction of relapse rate [84]. Furthermore, in patients
with a first demyelinating event suggestive ofMS, a 50 nmol/l
increment of average serum levels within the first 12 months
predicted significantly lower rates of relapses, new active le-
sions, and a trend of lower brain volume loss in the following
5 years [87]. A very interesting recent study suggested a rela-
tion of the severity of neuro-axonal retinal damage after optic
neuritis and serum vitamin D levels, in that retinal damage
was substantially lower in patients with high vitamin D levels
with men having greater retinal nerve fiber layer and ganglion
cell layer thinning than women [89]. In summary, data consis-
tently show a clear association between higher vitamin D
levels with a less active disease course. However, data are
not sufficient to prove a causal relationship.
Interventional clinical trials
The few interventional trials undertaken so far to investigate
whether vitamin D supplementation can beneficially influence
the disease course have been methodologically fairly hetero-
geneous, and study designs have not always been appropriate.
Some studies were not longitudinal, and other confounding
factors such as the outdoor activity of patients and sunlight
exposure were not considered. Not surprisingly, results of
these trials are rather inconsistent. A small and uncontrolled
study focusing on safety demonstrated that short-term doses
up to 280,000 IU/week over a 28-week period are safe in MS.
A possible effect on gadolinium-enhancing MRI lesions but
not on clinical outcome parameters was observed [90]. Two
randomized double-blind and placebo-controlled short-term
trials showed a significant shift from a pro- to a rather anti-
inflammatory serological cytokine pattern [91, 92]. Another
randomized and controlled but open-label study comparing
doses up to 40,000 or 4000 IU cholecalciferol per day for
12 months in 49 MS patients showed a significantly reduced
relapse rate in the high dose arm. Two randomized, double-
blind and placebo-controlled studies using 20,000 IU chole-
calciferol per week also failed to detect significant effects on
clinical parameters of disease activity although one study
showed significantly fewer gadolinium-enhancing lesions on
brain MRI [93, 94]. Another study investigated vitamin D2
(VD2) effect in relapsing-remitting MS patients. All partici-
pants received 1000 IU VD2 daily (on ethical grounds to
prevent deficiency) while the high-dose arm additionally re-
ceived 6000 IU for a period of 6 months. The results from this
study could not show any effect of vitamin D2 in terms of
clinical and MRI parameters [95]. Accordingly, a meta-
analysis of five clinical trials found no significant effect of
high-dose vitamin D on the risk of relapse in MS [96].
Results of the randomized double-blind and placebo-
controlled SOLAR (NCT01285401) study, which addressed
the effect of 14,000 IE cholecalciferol add-on to interferon
beta on clinical and MRI parameters in 229 RRMS patients,
were presented at the 2016 ECTRIMS meeting in London,
UK. While the primary endpoint (no evidence of disease ac-
tivity) was missed, a trend to a 30% relapse rate reduction, not
reaching statistical significance, and a significant 32% reduc-
tion of active MRI lesions (both gadolinium-enhancing and
T2 lesions) was reported.
A US single-center randomized double-blind control trial
involving 40 MS patients between 18 and 55 years, receiving
either a high dose (10,400 IU) or low dose (800 IU) daily for
6 months, showed reduced IL-17 production and effector
memory CD4+ T cells in the higher dose arm. This study,
although with small sample size, adds to the knowledge on
the immunomodulatory effect of vitamin D in MS [97].
However, the question whether vitamin D positively impacts
the course of MS is still not answered. Several interventional
studies investigating the effect of vitamin D on disease sever-
ity either by supplementation with vitamin D as add-on ther-
apy or UVB phototherapy are ongoing [98–101].
The EVIDIMS study is a German multi-center randomized
double-blind phase II trial which aims to investigate the effect
of vitamin D supplementation as add-on therapy to
interferon-β1b treatment with patients grouped into high-
dose and low-dose arms [99] while the VIDAMS trial inves-
tigates the effect of vitamin D onMS after a 1 month treatment
with glatiramer acetate in high-(5000 IU) and low-dose arms
(600 IU) [98].
In conclusion, meanwhile, a huge body of evidence points
towards a less active course of MS in the presence of high
serum vitamin D. However, the ultimate question of whether
and howmuch vitamin DMS patients should take can still not
be answered on scientific grounds. Additionally, a Breal-
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world^ study investigating the association between serum vi-
tamin D levels on disease course in patients with disease-
modifying drugs of MS such as interferon-β, glatiramer ace-
tate and fingolimod found differences in the effect of serum
vitamin D levels on the relapse rate and gadolinium-
enhancing lesions in the different treatment classes. The risk
of relapse was lower in the interferon-β cohort alone (HR,
0.58) or in the combined interferon-β and glatiramer acetate
cohort (HR = 0.77) compared to the glatiramer acetate cohort
alone (HR = 0.89). Also, the effect of vitamin D on
gadolinium-enhancing lesions was more pronounced in the
interferon-β treated group (HR = 0.41). In fingolimod treat-
ment patients, serum vitamin D did not have any significant
effect on gadolinium-enhancing lesions. This suggests that the
effect of vitamin D may also be influenced by the type of
therapy the patient is already receiving [102]. In a randomized
double-blind controlled trial, the effect of alfacalcidol, a syn-
thetic analogue of vitamin D on MS-related fatigue (assessed
by the Fatigue Severity Scale, FSS), was investigated in pa-
tients with mean age 41.1 ± 9.2 years and disease duration of
6.2 ± 5.5 years. Treatment with 1 mcg/d of alfacalcidol for
6 months reduced the mean relative fatigue score to − 41.6%
compared to − 27.4% in the placebo group with improved
quality of life [103]. In sum, patients with inadequate vitamin
D levels (< 30 ng/ml / 75 nmol/l) should either be supplement-
ed with vitamin D or should be exposed to more sunlight in
order to achieve levels between 100 nmol/l (40 ng/ml) and
150 nmol/l (60 ng/ml) [4, 104, 105].
Neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSD) are
inflammatory autoimmune conditions of the central ner-
vous system predominantly affecting the optic nerve,
brainstem, and spinal cord; however, fatigue, pain, de-
pression, and sleep problems are also frequent symptoms
[106–109]. For a long time, NMOSD were considered
rare variants of MS; however, the seminal detection of a
highly specific serum biomarker, antibodies to the astro-
cyte water channel aquaporin-4, in up to 80% of patients
with a NMOSD phenotype, as well as subsequent immu-
nological, biomarker, and imaging studies made clear that
NMOSD is an autoimmune disease entity distinct from
MS [110–117]. Accrual of irreversible neurological dis-
ability is usually faster and long-term prognosis poorer
than in classical MS [118, 119]. For clinical management,
it is important to bear in mind that many classical immu-
nomodulatory drugs given in MS are inefficacious or even
harmful in NMO [120–123]. Recently, antibodies to my-
elin oligodendrocyte glycoprotein (MOG) were reported
in a subset of patients with a NMOSD phenotype sero-
negative for aquaporin-4 antibodies [124–127] and some
patients with MS [128, 129]. There is an ongoing scien-
tific debate as to whether adult patients with MOG anti-
bodies should be diagnosed with NMOSD or whether
MOG-antibody associated encephalomyelitis is a disease
entity in its own [130, 131].
Few studies have investigated vitamin D levels in pa-
tients with NMOSD. One study from Korea reported sig-
nificantly lower vitamin D levels in 51 NMOSD patients
seropositive for aquaporin-4 antibodies as compared to
204 healthy controls [132]. Although in patients, there
was no difference in vitamin D levels between relapse
and remission and no association with the annualized re-
lapse rate, higher vitamin D levels were associated with
less neurological disability measured by the Expanded
Disability Status Scale (EDSS). A recent study from
Thailand compared vitamin D levels in 20 patients with
clinically isolated syndrome (first manifestation of MS),
34 patients with MS, and 76 patients with NMOSD [133].
Prevalence of vitamin D insufficiency and deficiency
(< 30 ng/ml or 75 nmol/l) ranged from 73 to 80%, without
a difference between groups and no association with dis-
ease activity and neurological disability. Conversely, a
Chinese study reported lower vitamin D levels in 58
NMOSD patients versus 116 healthy controls and lower
levels in 43 NMOSD patients measured during relapse
compared to 15 NMOSD patients in remission [134].
The authors moreover reported an inverse correlation be-
tween the EDSS during attacks and vitamin D levels.
Another study from Turkey found lower vitamin D levels
in 24 NMOSD patients and 19 MS patients compared to
22 healthy controls [135]. Neither did aquaporin 4 anti-
body status influence vitamin D levels nor was there a
correlation between vitamin D levels and age, number of
relapses, and EDSS scores. It is important to keep in mind
that none of these studies was longitudinal in design, and
it is thus not possible to adequately address the problem
of reverse causation discussed in the MS section above.
Two earlier studies had investigated the association be-
tween vitamin D levels and inflammatory spinal cord dis-
ease, a subgroup of which had a final diagnosis of
NMOSD [136, 137]. Vitamin D levels were significantly
lower in patients who had monophasic spinal cord inflam-
mation compared to recurrent disease, and vitamin D in-
sufficiency (< 30 ng/ml) was associated with a fourfold
(CI 1.60–10.0) increased risk of recurrence, along with
other predictors of recurrent disease. To date, there are
no studies that specifically investigated vitamin D levels
in patients with MOG antibodies.
In sum, despite inconclusive results from the few
studies above, it is in light of the devastating disease
course of many NMOSD patients and the significantly
increased risk of recurrence following a first episode of
myelitis in case of vitamin D insufficiency advisable to
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measure vitamin D levels in patients with NMOSD and
to raise these to above 30 ng/ml (75 nmol/l).
Role of vitamin D in Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease of the
central nervous system characterized by tremor, rigidity, bra-
dykinesia, postural imbalance resulting in falls, and severe
psychiatric symptoms like depression and dementia
[138–140]. It is the second most common progressive neuro-
degenerative disease affecting more men than women with the
incidence rate differing between ethnicities and increasing
with age [141]. Although the exact causes remain elusive,
genetic and environmental factors contribute to the disease
risk. PD patients tend to have lower vitamin D levels associ-
ated with low bone mineral density contributing to disease-
related disability [37].
Recent epidemiological studies have shown that low vita-
min D levels are more prevalent in PD patients compared to
healthy subjects, and low serum or plasma vitamin Dmay be a
predictive marker for PD risk and severity. In PD patients with
a mean age of 65 years, a 400 IU per day vitamin D supple-
mentation should reduce the risk of fractures by 20% [142].
Studies from North America and China investigating the role
of vitamin D levels in PD patients found an association be-
tween plasma and serum vitamin D levels and disease severity
(measured by the Hoehn and Yahr stage and the Unified
Parkinson’s Disease Rating Scale (UPDRS)). In the North
American study, 17.6% of the 388 PD patients had vitamin
D deficiency (< 30 ng/ml (75 nmol/l) [10] compared to 9.3%
of the 283 age-matched healthy controls (30.6 ng/ml) [143]. In
this study, not all patients had vitamin D deficiency and some
healthy controls were also not vitamin D deficient. This draws
attention again to the issue of reverse-causation as explained
above. The studies failed to assess the activities of patients and
even healthy controls with regard to sunlight exposure, out-
door activities, or even dietary vitamin D intake.
In the Chinese cohort involving 229 PD patients and 120
age-matched healthy controls, serum vitamin D levels were
significantly lower (< 20.6 ng/ml) in PD patients compared to
22.9 ng/ml in healthy subjects [144].
Therapeutic effects of vitamin D in animal models of PD
The loss of dopaminergic neurons is amajor characteristic of PD;
hence, therapeutic approaches have focused on finding ways to
restore the dopaminergic neurons in the substantia nigra [145].
Animal models of PD have been often used to test the
efficacy of vitamin D in the disease pathology in terms of
dopamine production, neurotrophic factors synthesis, as well
as the possible neuroprotective effect of vitamin D. In a rat
model of PD, intraperitoneal injection of 1,25(OH)2D3 before
or after inducing PD partially restored tyrosine hydroxylase
expression in the substantia nigra [146] thus promoting the
conversion of tyrosine to dopamine. Another rodent study,
investigating the effect of vitamin D on zinc-induced neuro-
toxicity in the substantia nigra of rats, found that vitamin D
reduced oxidative injury in the substantia nigra [147].
Genetic studies focusing on vitamin D receptor polymor-
phisms have also shown an association between vitamin D
and PD [148–150]. The response to vitamin D treatment
may be partially or fully influenced by VDR gene variants.
Using healthy mice to test the effect of vitamin D on motor
functions, vitamin D receptor knockout mice showed im-
paired motor functions evident in the swim test, with signifi-
cantly reduced immobility duration compared to the wildtype
counterparts [151].
Interventional and genetic clinical studies
There are very few interventional studies that have been un-
dertaken to investigate a potentially beneficial effect of vita-
min D on the disease course in PD. The human studies have
focused on the polymorphisms of vitamin D receptors. The
findings from most human observational studies have been
inconsistent due to different population characteristics and
confounding variables such as seasonal changes, diet, and
genetic variations of the VDR among others.While most stud-
ies have shown that sufficient vitamin D status (> 30 ng/ml)
and the expression of particular VDR gene variants may ame-
liorate disease severity, one study conducted in the Faroe
Islands could not establish any relationship between serum
25(OH)D or VDR polymorphisms on PD [152].
In a 29-year longitudinal study involving 3173 men and
women between the ages of 50 to 79 years from Finland
who were free from PD at baseline, individuals with high
serum vitamin D levels (> 20 ng/ml or at least 50 nmol/l)
had 65% reduced risk of PD compared to those with low
serum vitamin D levels (< 8 ng/ml or 25 nmol/l) [6].
Moreover, some of the clinical presentations of PD such as
falls, fractures, and balance problems have been attributed to
low levels of circulating vitamin D [17, 148, 153].
The link between vitamin D and PD worsening could be
explained by the fact that VDRs are highly expressed in the
substantia nigra [7], a key anatomical region involved in PD
pathogenesis.
The VDR which is located on chromosome 12q13.1 has
numerous polymorphisms located on different exons at the
promoter region of the VDR. The most characterized are the
FokI allele with different variants such as the homozygous
FokI TT/CC or a heterozygous FokT/C on exon 2, the BsmI
on exon 8, and the ApaI and TaqI on exon 9 [154, 155].
Different alleles of the VDR have been shown to affect PD
differently. Suzuki and colleagues in a randomized double-
blind study involving 104 PD patients who received
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1200 IU of vitamin D per day for 12 months assessed the
effect of vitamin D in PD [148]. In this study, the Hoehn
and Yahr scale and the UPDRS were used to assess disease
severity. Patients that received vitamin D supplements had
better disease rating compared to the placebo group.
Investigating the effect of vitamin D on the genetic level re-
vealed that carriers of the FokI TT allele responded better to
vitamin D treatment, the FokI CTcarriers had moderate effect,
while the FokI CC carriers [148] showed no effect of vitamin
D.
In contrast, two other studies investigating the effect of
VDR polymorphisms in PD found that the FokI T/C allele
was associated with PD. The FokI C allele was predominant
in PD patients than in healthy controls in Chinese and
Hungarian populations [149, 150].
In conclusion, evidence from both human and animal stud-
ies point to a beneficial effect of vitamin D in PD, although
few studies suggest otherwise.
Role of vitamin D in age-related cognitive decline
and Alzheimer’s disease
Alzheimer’s disease is a neurodegenerative disorder affecting
mostly elderly persons resulting in cognitive decline and de-
mentia [156, 157]. Worldwide, about 24 million people suffer
from the disease, and this number is expected to double by
2040 [158].The neuropathology of the disease is characterized
by neurofibrillary tangles and senile plaques in the brain. A
major hallmark of the disease is the accumulation of Aβ
plaques, a component of senile plaques caused by the prote-
olysis of amyloid-beta protein precursors [159]. It is speculat-
ed that the accumulation of Aβ induces inflammatory re-
sponses which account for the neurodegenerative component
of the disease resulting in cognitive decline [160, 161].
Although the causes of AD remain unknown, environmental
and genetic factors have been suggested to be associated with
the disease [162].
The most characterized genetic cause is attributed especial-
ly to the epsilon 4 (ε4) allele of apolipoprotein E (APOE)
[163, 164]. However, not all AD patients express the
APOEε4 allele which points to additional causative factors
[165, 166]. For example, low serum vitamin D levels
(< 30 ng/ml) and polymorphisms of the vitamin D receptor
have also been associated with AD.
Genetic studies of vitamin D in AD
The effect of vitamin D inAD can be explained by the fact that
VDRs are located in several regions of the brain, and low
VDR mRNAs were found in the brains of AD patients post-
mortem [167].
Most of the studies that have investigated the role of vita-
min D in Alzheimer’s disease were observational or genetic
studies.
A genetic study by Gezen and colleagues involving 104
late-onset AD patients showed that single nucleotide polymor-
phisms (SNPs) in VDR altered the vitamin D- receptor path-
way. The ApaI but not the TaqI polymorphism of the VDR
was found to be associated with AD [168, 169]. Other studies
focusing on the genetic variants of the VDR found associa-
tions between the BamI, TaqI alleles, and cognitive decline,
while the ApaI variant was associated with better cognition
[170].
Following these findings, Lehmann and colleagues found
that the ApaI and TaqI alleles were associated with risk of AD
with odd ratios of 3.1 (95% CI 1.4–6.7, p = 0.005) and 3.0
(95% CI 1.6–5.6, p = 0.0008) for patients below 75 years,
respectively [171]. These findings were confirmed in a study
involving Polish and British populations where carriers of
TaqI, ApaI, FokI, and BsmI showed a lower risk of AD
[172]. However, these alleles, especially ApaI, were not asso-
ciated with AD in the Turkish and Iranian population suggest-
ing that the association of VDR polymorphisms with ADmay
be influenced by the ethnicity of the patient [172].
Interventional studies in animal models of AD
Interventional animal studies where rats received vita-
min D as dietary supplements (10,000 IU/Kg/day) for
5 to 6 months showed that rats with vitamin D supple-
ment performed better in the Morris water maze test, a
hippocampal-dependent learning and memory task, com-
pared to controls [21]. On the other hand, cognitive
impairment worsened when vitamin D was removed
from the diet of animals [21]. Furthermore, subcutane-
ous injections of 1,25(OH)2D3 reduced age-related cog-
nitive impairment in rats and also increased clearance of
Aβ plaques in older rats compared to the younger ones
[173].
The exact mechanism by which vitamin D mediates AD is
not clearly established. However, vitamin D reduces oxidative
stress thus preventing neurons from dying through the activa-
tion of macrophages which help Aβ plaques clearance as
shown in in vitro studies [30, 31]. One of the basic functions
of vitamin D is Ca homeostasis. However, in AD, the presence
of Aβ activates low-voltage calcium channels (LVCC) lead-
ing to Ca imbalance. In animal studies, vitamin D enhanced
Ca homeostasis and protected neuronal death by downregu-
lating LVCC induced by Aβ [34]. Offspring of rats depleted
of vitamin D supplementation had reduced nerve growth fac-
tor and glial-derived neurotrophic factor, and this was linked
with abnormal brain morphology such as enlarged ventricles
[174]. The clinical consequence is that pregnant women
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should have adequate vitamin D levels to avoid any develop-
mental defects.
Interventional clinical studies
A study in the USA investigated 1658 elderly adults (mean
age of 73.6 years) free from dementia or any cardiovascular
disease followed over a mean of 5.6 years (SD 1.6, median
6.1, range 0.1–8.4). Participants with severe vitamin D defi-
ciency (vitamin D levels < 25 nmol/l or 10 ng/ml) had higher
hazard ratio of 2.25 (95% CI 1.23–4.13), while participants
with vitamin D levels above 25 nmol/l–50 nmol/l (10 ng/ml–
20 ng/ml) had hazard ratios of 1.53 (95% CI 1.06–2.21) com-
pared to those with sufficient vitamin D levels (≥ 50 nmol/l or
≥ 20 ng/ml) to develop all-cause dementia. Of the 171 partic-
ipants who developed all-cause dementia, there were 102
cases of AD [15].
A randomized controlled double-blind placebo trial inves-
tigated the effect of vitamin D on cognition in healthy elderly
subjects above age 65 years. The vitamin D-supplemented
group (supplement contained 4.0 μg (160 IU) vitamin D and
other trace elements) had better cognitive performance
(p < 0.01) in the different cognitive tests (7 cognitive tests
including the Mini-Mental State examination) compared to
the placebo group [175].
A French study investigating the effect of dietary vitamin D
intake on cognition in older women with mean age of 75 years
and followed for 7 years showed that higher dietary intake of
vitamin D of 2336.41 IUweekly (mean baseline dietary intake
of 58.41 ± 30.09 μg/week (range 2.53–205.54)) reduced risk
of AD with adjusted odd ratios of 0.23 (95% CI 0.08–0.67)
compared to those with lower baseline vitamin D intake [176].
A limitation of this study is the fact that self-administering of
dietary vitamin D may result in false reports or perhaps insuf-
ficient quantities of vitamin D intake which may introduce
variations within the same group.
Furthermore, a meta-analysis of 37 studies comparing the
association between vitamin D levels and cognition using the
Mini-mental State Examinations scores showed a weak asso-
ciation between higher vitamin D levels (≥ 50 nmol/l or
≥ 20 ng/ml) with hazard ratio of 1.2 (95% CI 0.5 to 1.9:
I2 = 0.65; p = 0.002) and cognitive performance. The authors
explained that the heterogeneity in the methods used in
assessing vitamin D concentrations may account for this [12].
In contrast to these findings, a randomized controlled trial
investigating the effect of vitamin D on cognitive and emo-
tional functioning in healthy young adults of mean age
21.8 years who received 5000 IU of vitamin D daily for
6 weeks could not show any positive association between
vitamin D and cognition [177]. The study is, however, limited
by the fact that participants were free from any chronic neu-
rological disease and had sufficient serum vitamin D levels
(> 76.6 nmol/l or > 30 ng/ml). Conversely, most studies
assessing the effect of vitamin D on cognition have focused
on the elderly populations with chronic neurological diseases
and concomitant low vitamin D levels.
However, this throwsmore emphasis on whether vitamin D
levels decrease with age and as to whether prolonged low
levels of vitamin D are associated with the incidence of dis-
eases in the adulthood thus highlighting the need to investigate
the effect of reverse causation more thoroughly.
Nevertheless, patients with cognitive impairments should
be tested, and those with low levels (< 30 ng/ml) should be
supplemented.
In summary, vitamin D supplementation should be encour-
aged in the elderly as well as AD patients to combat the pos-
sible detrimental sequelae of low serum vitamin D levels.
Conclusion and expert recommendations
Vitamin D deficiency presumably plays a causative role in the
pathogenesis and course of various neuroinflammatory and
neurodegenerative diseases. However, details of vitamin D
involvement particularly on the individual level remain to be
clarified, and evidence for vitamin D supplementation in indi-
cations other than bone health are confined to a few interven-
tional clinical trials conducted so far. Additionally, results of
these trials are at least in part inconclusive. As a result, for the
time being, evidence-based recommendations on vitamin D
supplementation doses or target serum levels are hardly pos-
sible. Serum vitamin D levels of 75 nmol/l (30 ng/ml) are safe
and may potentially exert therapeutic effects in some patients
with neurodegenerative and neuroinflammatory diseases such
as reduced disability worsening, improved bone health, and
improved cognition. Whether higher serum levels and/or a
personalized high-dose vitamin D supplementation are supe-
rior in the prevention or modification of individual disease
courses remains to be clarified. Additionally, prospective stud-
ies are needed to evaluate the eligibility of vitamin D-related
parameters in models or tools to predict the development or
course of diseases on an individual level.
Taking a more conservative point of view, we, therefore,
recommend for the time being that patients are tested for vi-
tamin D levels and that those with low levels are supplement-
ed in order to reach serum levels of about 75 nmol/l (30 ng/
ml). This target level may potentially be raised when future
studies suggest higher levels to be beneficial.
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